Hafslund Nycomed sets up in South Korea:
This article was originally published in Clinica
Hafslund Nycomed (Norway) has established a South Korean subsidiary, Nycomed Korea. The company plans to launch the non-ionic X-ray contrast medium, Omnipaque, as well as other contrast agents on the South Korean market, according to Pharma Koreana.
You may also be interested in...
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.